Research programme: glucocorticoid receptor II antagonists - Corcept Therapeutics

Drug Profile

Research programme: glucocorticoid receptor II antagonists - Corcept Therapeutics

Alternative Names: CORT 112716; CORT 113083; CORT 118335; CORT 122928; CORT 125281

Latest Information Update: 09 Aug 2016

Price : $50

At a glance

  • Originator Corcept Therapeutics
  • Class
  • Mechanism of Action Glucocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alcoholism; Alzheimer's disease; Amyotrophic lateral sclerosis; Cancer; Memory disorders; Metabolic disorders; Muscular dystrophies; Non-alcoholic fatty liver disease; Obesity; Post-traumatic stress disorders; Psychiatric disorders

Most Recent Events

  • 02 Aug 2016 Corcept plans phase I trials for CORT 118335, CORT 122928 and CORT 125281
  • 01 Apr 2016 Pharmacodynamics data from a preclinical trial presented at the the 98th Annual Meeting of the Endocrine Society (ES-2016)
  • 01 Jan 2015 Preclinical trials in Non-alcoholic fatty liver disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top